BioNexus Gene Lab Corp. Increase (Decrease) in Operating Liabilities
BioNexus Gene Lab Corp. (BGLC) reported Increase (Decrease) in Operating Liabilities of -$20.17 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLiabilities · last filed 2022-04-06
- BioNexus Gene Lab Corp. increase (decrease) in operating liabilities for fiscal 2021 was -$20.17K, a 151.81% decline from fiscal 2020.
- BioNexus Gene Lab Corp. increase (decrease) in operating liabilities for fiscal 2020 was $38.93K.
| Period end | Increase (Decrease) in Operating Liabilities 12 month |
|---|---|
| 2021-12-31 | -$20.17K 10-K · filed 2022-04-06 |
| 2020-12-31 | $38.93K 10-K · filed 2022-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |